3-substituted oxindole β-3 agonists
US6911463B2 · kind B2 · utility
5Cited by
6References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 6, 2002 |
| Grant date | Jun 28, 2005 |
| Priority date | — |
| Expiry date | Aug 6, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to a β3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.